The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...
Zydus Lifesciences announced two significant developments today. The company has reached an agreement with CVS Caremark to include its diabetes medications Zituvio, Zituvimet, and Zituvimet XR in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback